Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

Atopic Dermatitis

Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis

J Eur Acad Dermatol Venereol

Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M

doi: 10.1111/jdv.17351

PsoriasisFurther Publications Dermatology

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up

Br J Dermatol

Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C

doi: 10.1111/bjd.20595

Psoriasis

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis

JAMA Dermatol.

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M

doi: 10.1001/jamadermatol.2019.4029.

Osteoarthritis

Effects of long-term exercise therapy on knee joint structure in people with knee osteoarthritis: A systematic review and meta-analysis

Semin Arthritis Rheum.

Van Ginckel A, Hall M, Dobson F, Calders P

doi: 10.1016/j.semarthrit.

Psoriasis

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials

J Eur Acad Dermatol Venereol.

Langley RG, Kimball AB, Nakagawa H, Xu W, Pangallo B, Osuntokun OO, Agada N, Reich K

doi: 10.1111/jdv.15242.

Psoriasis

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

JAMA Dermatol.

van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ

doi: 10.1001/jamadermatol.

Psoriatic Arthritis

Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis

Semin Arthritis Rheum.

Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y

doi: 10.1016/j.semarthrit.

Psoriasis

Long-Term Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis: Phase 3 Open-Label Study

J Eur Acad Dermatol Venereol

Lebwohl MG, Stein Gold L, Papp K, Han G, Pariser DM, Lin T, Harris S, Jacobson A

doi: 10.1111/jdv.17113

Psoriasis

Absolute and relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes

Acta Derm Venereol.

Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C

doi: 10.2340/00015555-3245.

Related content

Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis

Effects of long-term exercise therapy on knee joint structure in people with knee osteoarthritis: A systematic review and meta-analysis

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis

Long-Term Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis: Phase 3 Open-Label Study

Absolute and relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes